Needham Maintains Their Hold Rating on Masimo (MASI)

Needham analyst Michael Matson maintained a Hold rating on Masimo (MASIResearch Report) today. The company’s shares closed last Monday at $242.67.

According to TipRanks.com, Matson is a 5-star analyst with an average return of 17.4% and a 71.8% success rate. Matson covers the Healthcare sector, focusing on stocks such as Axonics Modulation Technologies, Cardiovascular Systems, and Zimmer Biomet Holdings.

Currently, the analyst consensus on Masimo is a Moderate Buy with an average price target of $297.50, which is a 20.3% upside from current levels. In a report released yesterday, BTIG also maintained a Hold rating on the stock.

See today’s analyst top recommended stocks >>

Masimo’s market cap is currently $13.35B and has a P/E ratio of 59.30. The company has a Price to Book ratio of 11.01.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Masimo Corp. is a medical technology company, which develops, manufactures and markets non invasive patient monitoring technologies, medical devices and sensors. Its products include continuous monitors, patient-worn monitors, hospital automation connectivity, capnography & gas, data download & analytics and sensors & accessories. The company was founded by Joe E. Kiani in May 1989 and is headquartered in Irvine, CA.